Thresholds for efficacy outcomes in psoriatic arthritis vary according to baseline disease activity but not according to prior tumour necrosis factor inhibitor treatment

Journal:
Annals of the Rheumatic Diseases
Published:
DOI:
10.1016/j.ard.2026.03.032
Affiliations:
11
Authors:
8
Go to article
Institutions Authors Share
Johnson & Johnson, United States of America (USA)
2.000000
 0.25
Johnson & Johnson (Middle East) Inc., United Arab Emirates
1.000000
 0.13
University of Pennsylvania (Penn), United States of America (USA)
1.000000
 0.13
NIHR Leeds Biomedical Research Centre, United Kingdom (UK)
0.750000
 0.09
Pierre Louis Institute of Epidemiology and Public Health (iPLESP), France
0.666667
 0.08
McGill University, Canada
0.666667
 0.08
Providence Swedish, United States of America (USA)
0.666667
 0.08
AP-HP Pitié-Salpêtrière Hospital, France
0.333333
 0.04
JSS Medical Research Inc., Canada
0.333333
 0.04
UW Medicine, United States of America (USA)
0.333333
 0.04
University of Leeds, United Kingdom (UK)
0.250000
 0.03
Interested in Clinical Sciences?